Navigation Links
Will 'botox' be the aspirin of the 21st century?
Date:3/18/2008

Oxford, UK 25 March 2008 The journal Medical Hypotheses (http://www.elsevier.com/locate/mehy), an Elsevier publication, has announced the winner of the 2007 David Horrobin Prize for medical theory. Written by Erle CH Lim and Raymond CS Seet of the Yong Loo Lin School of Medicine, National University of Singapore, the article, Botulinum toxin, Quo Vadis? was judged to best embody the spirit of the journal.

Botulinum toxin (botox) is a very powerful and often fatal poison produced by a rare type of food poisoning bacteria. The toxin blocks the activity of cholinergic nerves which control muscles and glands, causing glands to stop secretion and muscles to become paralysed. But in tiny doses and applied to specific structures, botox has many medical uses. Lim and Seets paper describes the early medical use of botulinum toxin in treating eye-squint, then its wider role in treating pain, excess glandular secretion and muscle spasm disorders, and its best-known use as a wrinkle remover in cosmetic surgery.

The authors go on to suggest a wide range of possible uses for botox such as calming restless legs, improving breathing in asthma, reducing sweating, and performing a chemical liposuction by removing excessive fat. In theory, botulinum toxin might be used to treat a broad range of pain syndromes, and to reduce activity for all types of glands and muscles that receive their nerve supply from the cholinergic system.

This judge for this years prize was the internationally famous neuroscientist VS Ramachandran of the University of California at San Diego, USA. Professor Ramachandran described the paper as: "A scholarly overview containing many suggestions for potentially valuable new directions of research"

The 1,000 prize was launched in 2004 and is awarded annually by Elsevier, the publisher of Medical Hypotheses. It is named in honour of Dr. David Horrobin, the renowned researcher, biotechnology expert and founder of Medical Hypotheses, who died in 2003.


'/>"/>

Contact: Ian Salusbury
ian.salusbury@elsevier.com
44-186-584-3824
Elsevier
Source:Eurekalert

Related medicine news :

1. GFX: Wrinkle-Killer or Botox(R) Hit-Man?
2. Founding Father of Modern Cosmetic Dermatology Seeks to Warn Public of Misrepresented Data and Inappropriate Use of Botox
3. Clarity for Consumers on Botox Complication and Death Reports
4. AAFPRS Speaks to the Safety of BOTOX(R) Cosmetic
5. Botox Cosmetic Alternatives Are Available: Surgical Procedures Offer Solution for Wrinkles
6. FDA Warns of Childrens Deaths Linked to Botox
7. The American Society for Aesthetic Plastic Surgery Addresses the Safety of Botox
8. American Society for Dermatologic Surgery Supports Current Labeling of Allergans Botox(R) Products
9. ASPS Addresses Concerns Regarding BOTOX Treatments
10. Men need more Botox than women
11. UT Southwestern urologist uses Botox to treat debilitating condition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... February 13, 2016 , ... The producers of Enterprises ... businesses. , The increasingly modern world of instantaneous consumption proves very convenient for ... sources such as oil and coal, which pollutes our air, water, and soil. It ...
(Date:2/13/2016)... ... February 13, 2016 , ... In the early or “honeymoon” stage of ... perfection, go out of their way to be romantic, and may exaggerate a strength ... at any online dating profile. , A recent study from Queendom.com , ...
(Date:2/12/2016)... ... 12, 2016 , ... The law firm of Morrow, Morrow, Ryan & Bassett ... of these scholarships is to encourage applicants to pursue a degree in their field ... two parishes. , “We have available jobs in St. Landry and Evangeline Parishes ...
(Date:2/12/2016)... VA (PRWEB) , ... February 12, 2016 , ... ... Feb. 29, 2016 — 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination ... in the life cycle of pharmaceutical products, garnering increased attention from all stakeholders ...
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., a technology ... for the ISE Southeast Awards 2016. Finalists and winners of the ISE® Awards ... Executive Forum and Awards Gala on March 15, 2016 at the Westin Peachtree ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Ky. , Feb. 12, 2016 /PRNewswire/ ... has completed a $47.1 million Series D ... Cormorant Asset Management, Hillhouse Capital Group and ... Morningside Venture Investments, AJU IB Investment, and ... be used to further advance clinical trials ...
(Date:2/11/2016)... 11, 2016 The primary goal of this ... patterns on the usage of liquid biopsy. Key information ... - Timeframe of liquid biopsy adoption amidst future ... Evs—by organization type - Sample inflow to conduct liquid ... stool, serum, and so on. - Correlation analysis of ...
(Date:2/11/2016)... , Feb. 11, 2016  Kindred Biosciences, Inc. (NASDAQ: ... and improving the lives of pets, today announced the ... the New Animal Drug Application (NADA) for Zimeta™ (dipyrone ... study (KB0120) of Zimeta for the control of pyrexia ... --> --> The ...
Breaking Medicine Technology: